restart flower 04

Restart
your life

relax flower 4

relax
the diastolic heart

patients image

There Are More Than

26 MILION PATIENTS

Around The World Suffering From Heart Failure

50% Of These Patients Have No Significant Benefit From The Currently Available Drugs Or Device Treatments And REMAIN UNTREATED

corrola-matrix
CorAssist has developed a cardiac implant that can dramatically change the life of these untreated patients

CorAssist Presents Its Uniquely Designed CORolla®

The CORolla®, an elastic spring-like device implanted inside the LV during a simple, minimally invasive procedure. The self-expanding device assists heart function by improving diastolic dynamics and filling performance.

problem-solution-matrix

the problem

  • No Long Term Treatment
  • Frequent Hospitalization And Complications
  • Healthcare Burden
  • Poor Quality Of Life For Patients
  • High Mortality Rates
Read More
problem-solution-matrix

the solution

heart4solution
  • Long Term implant
  • One Time Procedure
  • Reduces Health Care Expenditures
  • Self Operating Assist Device
  • Reversing The Vicious Cycle
Read More

Main features

Harnesses the energy produced by the heart’s LV during systole (contraction) and releasing it back to the LV during diastole (Relaxation)
Enhances cardiac output by helping supply oxygenated blood to vital organs
Reduces LV diastolic pressure that causes pulmonary congestion
Does not require a power source, so there’s no maintenance (compared to implantable electronic devices)
Minimally invasive procedure, simple and safe (off-pump, transapical, or percutaneous approach)

Company status

2008

Development Begins
Completed
CorAssist starts developing the CORolla®

2010

Design
Freeze
Completed
Start V&V for the CORolla® device

2012

Pre-Clinical
Trials
Completed
Following the V&V, CorAssist started the testing on animals

2017

First
Implantation
Completed
Corasist performed the first implantation in a man

2020

Industrialization
And Testing
Current Stage
Produce devices for clinical study, scale up production

2021

FIH
Clinical Study
Current Stage
Perform First-In-Human clinical study to validate the safety of the device

2022

Multi Site
Trial
Further Develompment
Perform a multi site clinical trial in Israel and EU

2023

CE
Approval
Further Develompment
CE Mark granted, First sales performed

2024

Reimbursement
Study
Further Develompment
Perform a study for Initial reimbursement

2025

FDA
Clearance
Further Develompment
contact-width-matrix
contact-matrix

Contact Us

    CorAssist Cardiovascular Ltd.
    57 Derech Ha’atzmaut,
    PO Box 33066,
    Haifa 3303329, Israel

    +972-58-680-7010 yairfeld@gmail.com
    © Corassist Cardiovascular Ltd. All rights reserved
    Site by Imaginet